Human embryonic stem cells (hESCs) have the potential to be a promising source of liver cells, hepatocytes, for regenerative medicine given their unlimited proliferative and pluripotent differentiative capacity. However, the inefficient embryoid body process and limited understanding of molecular signals potentiating cell-specific differentiation plague the use of hESCs as a hepatic source. In this study, we describe an efficient growth factor-based process for directed differentiation of hESCs that bypasses embryoid body development. The system involves adherent hESC culture exposure to activin A treatment followed by incorporation of various growth factor combinations composed of dexamethasone, oncostatin M, hepatocyte growth factor, and Wnt3A. The hESC-derived hepatocyte-like cells resulting from optimal growth factor combinations exhibit characteristic hepatocyte morphology, express hepatocyte markers, and possess hepatospecific functional activity. The differentiated cultures express hepatic-related genes shown by reverse transcription-polymerase chain reaction and immunofluorescence analysis revealed binucleated cells with coexpression of albumin/cytokeratin 18. Furthermore, the hESC-derived hepatocyte-like cells exhibit functional hepatic characteristics, such as indocyanine green uptake and release, albumin secretion, and inducible cytochrome P450 activity. This directed differentiation of adherent hESCs offers an efficient process to produce hepatocyte-like cells in vitro for hepatocyte differentiation studies and organotypic cultures for diagnostic and therapeutic applications. ava i l a b l e a t w w w. s c i e n c e d i r e c t . c o m w w w. e l s ev i e r. c o m / l o c a t e / s c r Stem Cell Research (2009) 3, 51-62
Introduction
The field of stem cell bioengineering can potentially revolutionize cell-based therapies for functional replacement of metabolically complex tissues like that of the liver (McKay, 2000; Mitaka, 2002; Miyashita et al., 2002; Daley, 2002; Fair et al., 2003) . Significant challenges notwithstanding, human embryonic stem cells (hESCs) offer a promising cell source for transplantation medicine, particularly with the active efforts underway to guide embryonic stem (ES) cell development and maturation (Choi et al., 2002; Hu et al., 2004; Shirahashi et al., 2004) . The ES cell model was recently demonstrated to be highly organotypic based on its successful realization of specific lineages (Kubo et al., 2004a) ; however, molecular signals that can effectively promote the integration and hepatospecific differentiation of ESCs are only now beginning to be clarified (Selden and Hodgson, 2004; Strain and Neuberger, 2002) .
The ability of healthy human liver to regenerate is steadily lost in chronic liver disease. The standard treatment for advanced liver disease, which is the eighth leading cause of adult deaths globally, has been orthotopic liver organ transplantation, but this therapy is limited by the availability of donor tissue (Harper and Rosendale, 1996; Susick et al., 2001) . Cell transplantation of liver parenchymal cells, hepatocytes, was shown to be an effective strategy in animal models of hepatic failure and metabolic liver diseases (Kobayashi et al., 2000; Strom et al., 1999) ; hepatocyte transplantation has also been shown to be a plausible treatment in human metabolic liver disease (Malhi and Gupta, 2001; Fox et al., 1998) . Hepatocyte engineering continues to be an active field of investigation that has brought the key issues of cell sourcing and organoid definition to the forefront of the field of tissue engineering (Griffith and Naughton, 2002; Allen and Bhatia, 2002) . In addition to hepatocyte-based therapies, hepatocyte cultures are widely considered as diagnostic in vitro models for preclinical functional and toxicogenomic screening of pharmaceutical drugs (Harries et al., 2001; Modriansky et al., 2000) . However, the utility of hepatocytes in either clinical or pharmaceutical applications is limited by their availability and variability, as well as their limited proliferation and decline in hepatic functions on extended in vitro cultures.
Embryonic stem cells afford a promising source of hepatocytes given their unlimited proliferative and pluripotent differentiative capacity (Hu et al., 2004; Chinzei et al., 2002; Jochheim et al., 2004; Kania et al., 2004) . Human embryonic stem cells are derived, mechanically or immunosurgically, from the polarized inner cell mass of a preimplantation-stage blastocyst (Reubinoff et al., 2000; Thomson et al., 1998) . Spontaneous differentiation of hES colonies rapidly occurs in vitro when the system lacks preventative factors, such as basic fibroblast growth factor (bFGF). In twodimensional systems, spontaneous differentiation occurs at the outer borders of the colonies, at fusing colonies, or at the center core where cells begin to pile up (Sathananthan et al., 2002) . A three-dimensional culture system, in the form of embryoid bodies, is another way to initiate differentiation of hES cells (Itskovitz-Eldor et al., 2000) . The appearance of all three germ layers is possible in this suspension culture system. Selecting specific cell-type populations can be achieved with cell-surface markers and separation techniques, although these procedures remain difficult to scale-up and inefficient (Levenberg et al., 2002) . The process of directed differentiation is defined by induction into a specific cell type, without the presence of all three germ layers and can be enhanced by endogenous transcription factor activation, transcription factor transfection, growth factor supplements, or coculture environments (Pera and Trounson, 2004; Trounson, 2005) .
Endodermal differentiation from hESCs remains a challenge due to an incomplete understanding of the differentiation process; therefore several investigators have utilized complex processes to induce hepatic-like differentiation of hESCs in both two-and three-dimensional culture systems in vitro. A few successful approaches have supplemented traditional embryoid body development by growth factor treatment and the use of collagen scaffold systems (Baharvand et al., 2006) or were enriched by reporter gene purification by a hepatocyte-specific promoter to differentiate hESCs (Lavon et al., 2004) . Treatments incorporating dimethyl sulfoxide and sodium butyrate have induced hepatocyte markers in two-dimensional cultures of hESCs (Rambhatla et al., 2003) . Baharvand and Shahsavan have proposed an interesting 28-day method that utilizes a multistep protocol of growth factors to mediate hepatocyte-like differentiation without the use of embryoid bodies or serum (Baharvand et al., 2008) . Similarly, Cai et al. created hepatic cells from undifferentiated hESCs through a 18-day three-stage method in serum-free medium (Cai et al., 2007) . Activin A, sodium butyrate, dimethyl sulfoxide, and oncostatin M were utilized to induce a differentiation process that takes up to 3 weeks to differentiate hESCs into hepatocyte-like cells (Hay et al., 2008a) . Recently, Hay et al. used activin A and Wnt3a to prime hESCs to induce hepatocellular function in vitro and in vivo (Hay et al., 2008b) . Various groups have used a plethora of growth factors and extracellular matrixes to induce hESC hepatic differentiation (Ishii et al., 2008; Agarwal et al., 2008) . Each of these systems takes several days or weeks to differentiate the hESCs, but the challenge still remains to create a direct and efficient process for directed hepatic differentiation.
Largely inspired by the in vivo progression of hepatotrophic stimuli during development (Duncan, 2000 (Duncan, , 2003 , there have been extensive studies of molecular growth factors that can interact with developing liver cells, fetal liver cells, and, more recently, embryonic stem cells (Shirahashi et al., 2004; Rambhatla et al., 2003; Rossi et al., 2001; Michalopoulos et al., 2003; Dasgupta et al., 2005; Levenberg et al., 2003; Schwartz et al., 2005) . A complex sequence of hepatotrophic factors has been implicated in the process of liver development (Zaret, 2001) . The interaction between the endoderm and cardiac-mesoderm is crucial for hepatic development (Cascio and Zaret, 1991) . This process results in the expression of two major liver-specific markers alpha-fetoprotein (AFP) and albumin (ALB), which can be detected as early as embryonic Days 8-9 (E8-E9). Hepatic cells at this point can differentiate into parenchymal hepatocytes or bile duct epithelial cells. At E10-11, hematopoietic stem cells originating from the extrahepatic organ colonize the fetal liver region and proliferate: hepatic progenitors participate in creating a conducive hematopoietic microenvironment (Mukouyama et al., 1998) ; in parallel, hematopoietic cells produce cytokines, especially oncostatin M (OSM), (Kamiya et al., 2001) while mesenchymal cells (nonparenchymal liver cells) produce the hepatocyte growth factor (HGF) (Kamiya et al., 1998) , a mitogen and morphogen, one of the key signals for liver development and regeneration (Huh et al., 2004) . The cooperative nature of signals required for hepatic maturation is best exemplified by the role played by growth factors secreted from hematopoietic cells. The most significant of these include dexamethasone (DEX) and oncostatin M (Kamiya et al., 2001 (Kamiya et al., , 1998 Kinoshita and Miyajima, 2002; Kojima et al., 2000) . DEX is known to suppress AFP production (early hepatic marker) and DNA synthesis, while upregulating albumin (midhepatic marker) and alpha-1-antitrypsin (AAT, late hepatic marker) production. OSM, an interleukin (IL) 6 family cytokine, has been shown to upregulate AAT and HNF-4. The synergistic action of DEX and OSM has been found to specifically induce hepatic maturation in fetal liver E14.5 (Kamiya et al., 2001 (Kamiya et al., , 1998 ) through induction of morphological changes and upregulation of multiple liver-specific functions Matsui et al., 2002) . Activin A reacts through the activin/nodal signaling pathway and has been shown to induce definite endoderm differentiation (McLean et al., 2007) . The Wnt/beta-catenin signaling cascade is involved in the hepatic differentiation pathway and has been shown to induce hepatic endoderm by Wnt3A treatment (Fletcher et al., 2008) .
Although there is significant promise in the potential use of the above maturation factors for ES cell differentiation, the exclusive application of these factors leads to a differentiation process that is inefficient and uncontrolled, thus, an integrated and phased application of these factors based on the complex cross-functional signaling pathways may be necessary. The central premise of this study is that optimal exogenous growth factor presentation to the adherent hESCs during development can be used to controllably expedite the process of directed differentiation into the hepatic lineage, bypassing the use of poorly defined embryoid body development (see Fig. 1 ).
Results
Early hepatic-like differentiation in growth factor supplemented cocktail Previous studies in our laboratory have shown that the optimal growth factor cocktail for mouse ES hepatocyte-like differentiation is composed of the combination of DEX, OSM, and HGF (DOH) (Dasgupta et al., 2005) . Therefore, we examined the effects of DOH on the differentiative ability in adherent hESCs. As shown in Fig. 2 , there was pronounced AFP expression after 1 week in culture on MEFs in the presence of DOH media, whereas the H1 colony in complete media lacking DOH supplementation only had stage-specific embryonic antigen-4 (SSEA-4) staining, indicating proliferative abilities. After 2 weeks in culture, AFP was still present, though not as prominent, and had achieved cells with a larger cytoplasm to nuclear ratio. Our data indicate that early hepatic-like differentiation is achieved when the adherent cultures are presented with DOH supplementation. This suggests that DOH is an effective growth factor treatment for early differentiation of hESCs.
Time course of genetic expression of hepatospecific maturation markers in hESCs
Additional media supplementations were added to the DOH treatment in an effort to further differentiate the hESCs in adherent cultures. Activin A and Wnt3A were added in various combinations to DOH treatment and evaluated for hepatic differentiation over a 2-week time course. An A (activin A, ActA) placed after DOH indicated the presence of activin A throughout culture while an A placed before DOH denotes a priori activin A treatment for 4 days and removal, Undifferentiated hESCs were cultured on mitotically inactivated mouse embryonic fibroblasts. Following weekly passaging, differentiation is initiated by the spontaneous differentiation method of embryoid body development or the expedited process of growth factor supplementation in adherent culture. (B) The optimal media supplementation was selected from the table of growth factors.
followed by culture in the presence of the remaining growth factors. Real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for an early (AFP) and mid (ALB) hepatic marker was normalized to beta-actin mRNA levels and evaluated for levels compared to basal media ( Fig. 3 ). AFP levels were higher after 1 week compared to 2 weeks, indicating an increase in differentiation associated with AFP levels diminishing. Albumin levels were enhanced after 2 weeks in culture compared to 1 week, indicating increased differentiation in all growth factor combinations. For each data set, the treatments that started with activin A treatment (A d0-4 DOH and A d0-4 DOHW) showed high levels of differentiation compared to basal media.
Endoderm and hepatic-specific gene expression of high performers
The mRNA expression of endodermal and hepatocytespecific genes, such as forkhead box A2 (FOXA2), transthyretin (TTR), alpha-1-antitrypsin (AAT), hepatocyte nuclear factor-4 (HNF-4) and cytokeratin 18 (CK18) was observed in the DOH, A d0-4 DOH, and A d0-4 DOHW cultures during differentiation ( Fig. 4 ). Complete media showed downregulation of each marker, indicating suppression of hepatic differentiation. Additionally, as a comparison for spontaneous differentiation, the basal endodermal differentiation during the formation of embryoid bodies (EB) was evaluated for expression of each hepatic marker. FOXA2 and TTR were upregulated, indicating endodermal differentiation, but were downregulated for the hepatocyte-specific genes, AAT, HNF-4, and CK18. These results indicate that the highperformance media induce hepatic differentiation of hESCs in comparison to basal EB development, which produces limited endoderm differentiation in the absence of supplementation with exogenous growth factors.
hESC-derived hepatic cells exhibit hepatocyte-like functions
Each growth factor combination from Fig. 3 was evaluated for functional activity by albumin secretion for up to 2 weeks in adherent culture (Fig. 5A ). Albumin production continuously increased and reached maximal values at day 14 with the exogenous growth factor supplementation, A d0-4 DOH, resulting in the highest level of albumin secretion. Statistically significant albumin production, compared to basal media for the same day, was achieved by high-performance media, DOH, A d0-4 DOHW, and A d0-4 DOH, and was further investigated for late hepatic markers. These levels are on the same order of magnitude as hepatocarcinoma Hep G2 cells (Leclerc et al., 2004) , indicating that efficient hepatic differentiation is being achieved after only 14 days in adherent culture.
Hepatic metabolism was evaluated using an ethoxyresorufin O-de-ethylase (EROD) assay (Fig. 5B) . The hESC-derived hepatocyte-like cells were evaluated for inducible CYP1A2 activity since cytochrome P450 isoenzyme expression is indicative of hepatocellular function (Ek et al., 2007) . The data illustrate that CYP1A2 activity was elevated in all highperformance media (DOH, A d0-4 DOH, and A d0-4 DOHW) and barely detectable in the control, complete media, indicating that hESC-derived cells have the functional features of hepatocytes.
To confirm liver-like metabolic function, ICG uptake and release were evaluated for basal and high-performance media after 2 weeks in culture ( Fig. 5C ). Uptake and release of ICG may be used to identify hepatocytes in ES cell differentiation models (Yamada et al., 2002) . The images show ICG uptake and release 6 h later in DOH, A d0-4 DOH, and A d0-4 DOHW cultures. In contrast, the basal media did not have the capacity to take up ICG and release it later. The most pronounced uptake was achieved by DOH and A d0-4 DOH cultures, indicating that hESC-derived hepatic cells have the metabolic function to rapidly uptake and excrete ICG.
Expression of hepatocyte markers in hESC-differentiated cells
To evaluate the hepatic differentiation of hESCs in the highperformance media, we costained for hepatic markers, albumin and cytokeratin 18, for differentiation (Fig. 6) . The control, complete and basal media, resulted in negative ALB/CK18 staining, but DOH, A d0-4 DOH, and A d0-4 DOHW resulted in elevated levels of ALB/CK18. The highest level of ALB/CK18 was achieved in A d0-4 DOH media supplementation and displayed distinctively differentiated morphology, such as the emergence of binucleated cells and characteristic cuboidal phenotype.
To determine the percentage of cells expressing albumin and cytokeratin 18 throughout 4 weeks of culture, flow cytometry was utilized (supplemental data). Undifferentiated cells expressed no albumin and CK18 expression. At week 2, albumin (7.02%) begins to rise while CK18 (48.38%) is greatly upregulated. For long-term, terminal differentiation culture, at 4 weeks, 72.8% of cells are albumin positive and 72.9% are cytokeratin 18 positive. Therefore, A d0-4 DOH media supplementation is an efficient protocol to induce hepatic expression on a large population of cells.
Discussion
Methods to differentiate hESCs into hepatocytes must be direct, rapid, and offer high yields, in order to be widely useful for basic research and therapeutic applications. Here we describe an efficient protocol for exogenous growth factor stimulation to induce hepatocyte-like cells from hESCs without the use of embryoid bodies. Priming hESCs with activin A to induce endodermal differentiation followed by treatment with select growth factors that recapitulate hepatogenesis in vivo results in cells with characteristic hepatocyte morphology and that express hepatocyte markers and possess hepatospecific functional activity.
Pluripotent hESCs are preserved under very strict lab practices, usually in culture with embryonic or adult somatic cells that secrete products to maintain pluripotency. Traditionally, hESCs are cocultured with mitotically inactivated murine embryonic fibroblasts (MEFs) to form twodimensional colonies that must be maintained on a weekly basis and supplemented with basic fibroblast growth factor and TGF-β to help maintain self-renewal (Sato et al., 2004) . When these factors are removed from the culture and maintained under appropriate conditions, hESCs can differentiate into the three embryonic germ layers. To induce differentiation, researchers have taken advantage of embryoid body development to mimic the environment of the periimplantation embryo to force lineage restriction (Wang et al., 2008) . Traditional hepatic terminal differentiation results from progenitor cells isolated from the endoderm followed by exposure to the proper molecular cues. This entire process may take up to 28 days to derive EBs, subculture the endoderm, and culture with growth factors (Baharvand et al., 2006) . If the complex embryoid body process is bypassed, suitable growth factors will be necessary to recapitulate cues for differentiation into hepatocyte-like cells.
In our study, growth factor components for media supplementation were selected based on their published abilities to induce hepatic differentiation in embryonic stem cells. The initial growth factor selection for hepatic differentiation of hESCs stemmed from our previous work with mouse ES cells, concluding that the synergistic effects of dexamethasone, oncostatin M, and hepatocyte growth factor were optimal conditions for differentiation (Dasgupta et al., 2005) . Dexamethasone is a synthetic glucocorticoid involved in liver gluconeogenesis (Lavon and Benvenisty, 2005), oncostatin M induces fetal hepatocyte maturation through the gp130 signal transducer (Kamiya et al., 1999) , and hepatocyte growth factor supports hepatogenesis by activating the c-Jun pathways (Hay et al., 2007) . Our data suggest that the DOH combination is sufficient to induce a hepatic response from hESCs within a very short period of time. We then chose to investigate the addition of additional growth factors, activin A and Wnt3A, to further direct differentiation associated with DOH stimulation. Activin A has been previously shown to restrict visceral endoderm (Yasunaga et al., 2005) , induce definitive endoderm differentiation from hESCs (Jiang et al., 2007; D'Amour et al., 2005; Kubo et al., 2004b; Chen et al., 2006) , and was therefore assessed for incorporation with DOH treatments.
Pretreatment with activin A for 4 days (A d0-4 DOH, A d0-4 DOHW) was compared to constant activin A throughout the experiment (DOHA, DOHAW). Molecular analysis showed that the effects of basal DOH treatment could be improved on with the addition of activin A pretreatment, indicating that the hESCs are differentiating through a loss in AFP expression and that activin A induces the highest levels of early hepatic differentiation. This result is consistent with previous observations of hESC liver development in which the initial activin A treatment is an efficient signal to induce definitive endoderm differentiation. Additionally, Wnt3a was investigated for incorporation with DOH because of its known ability to induce hepatic endoderm (Fletcher et al., 2008) and Wnt3a expression has been demonstrated during human liver (Hay et al., 2008b) . Similar to our protocol, Wnt3a and activin A treatments were investigated to induce hepatic differentiation (Hay et al., 2008b) . Our system uses activin A priming to efficiently induce definitive endoderm, without the need for Wnt3a. Following activin A priming, the addition of Wnt3a alone was not sufficient to induce hepatic differentiation unless it was in conjunction with DOH treatment (data not shown), perhaps due to the fact that Wnt3a is downregulated after 3 days of endoderm specification (Hay et al., 2008b) . The synergistic effect of priming the hESCs with activin A and supplementing with DOH or DOHW induced significant hepatic differentiation compared to any single component alone (data not shown) or basal media controls. The addition of Wnt3a to DOH or ADOH Figure 5 Functional activity of hESC-derived hepatic-like cells. (A) Human albumin ELISA analysis of growth factor combinations. All albumin concentrations were increased during differentiation with three growth factor combinations resulting in significantly more albumin when compared to basal media for the same day. These results indicated that DOH, A d0-4 DOHW, and A d0-4 DOH result in the greatest level of differentiation. Data were analyzed in triplicate and displayed as mean ± SEM. All samples were analyzed by 400 μl of media supernatant. (⁎ denotes P b 0.05 compared to day 14 basal media.) (B) CYP1A2 activity in hESC-derived hepatic cells grown for 2 weeks in high-performance media, measured by EROD activity. Basal media showed minimal activity, whereas, the high-performance media had significant activity. Samples had no detectable levels of CYP1A2 activity prior to initiation. Data were analyzed in triplicate and displayed as mean ± SEM. (⁎ denotes P b 0.05 compared to complete media, § denotes P b 0.01 compared to complete media.) (C) ICG uptake and release. hESCs were grown for 2 weeks in culture in high-performance media and qualitatively evaluated for their ability to take up ICG (left column) and release it 6 h later (right column, shown at two different magnifications, 10X and 40X). Abbreviations: ICG, indocyanine green; CYP, cytochrome P450; EROD, ethoxyresorufin O-de-ethylase.
provides a system that lacks preventative factors, such as bFGF, TGF-β, to support differentiation (Dravid et al., 2005) .
To further determine the highest inducing growth factor combinations, functional activity (albumin secretion, cellular uptake and release of indocyanine green, and inducible cytochrome P450 activity) of the hESCs was analyzed. Consistent data from several approaches to quantify hepatic differentiation concluded that DOH, A d0-4 DOH, and A d0-4 DOHW treatments were deemed the highest performing combinations and were therefore further evaluated for their ability to induce differentiation. The high-performance cocktails (DOH, A d0-4 DOH, and A d0-4 DOHW) were characterized for their albumin and cytokeratin 18 staining and expression profiles. Albumin is a classic hepatic marker and often used in conjunction with CK18 to confirm coexpression. CK18 is perhaps the most commonly found member of the intermediate filament gene family and is indicative of hepatocyte morphology. All high-performance media showed ALB/CK18 staining, but the most striking staining associated with characteristic cuboidal morphology and the presence of double nuclei was found under the A d0-4 DOH conditions, indicative of hepatic differentiation. Flow cytometric analysis of undifferentiated and A d0-4 DOH-derived hESCs showed that in the presence of high-performance growth factors, over 70% of the cell population is ALB and CK18 positive after 4 weeks in terminal differentiation culture. These data reveal that the directed differentiation process largely yields cells that are hepatic in nature.
To determine whether most differentiated cells with morphological and functional characteristics also have genetic profiles of hepatocyte-like cells, the hESC-derived cells were evaluated for gene expression profiles for hepatocyte-associated markers. These hepatocyte nuclear factors are transcriptional activators for liver-specific transcripts such as albumin and transthyretin. All highperformance groups and EBs have higher expression of the transcription factor, FOXA2, found in the earliest stages of definitive endoderm, compared to complete media illustrating that the EB process can induce endoderm differentiation similar to DOH, A d0-4 DOH, and A d0-4 DOHW. Similar to FOXA2, transthyretin, or prealbumin, was found to be upregulated in all high-performance media and the EB condition. Further analysis of mid-late hepatic markers provides evidence that EB development alone cannot achieve hepatic differentiation on the levels associated with the high-performance media. Mid and late hepatic markers were evaluated and showed that alpha-1-antitrypsin was highly upregulated under the activin A pretreatment conditions while hepatocyte nuclear factor-4 and cytokeratin 18 were upregulated in all highperformance media, indicating that definitive endodermrestricted cells can achieve hepatocyte-like gene expression profiles with the selected growth factor regime. The insights gained from the gene expression profiles demonstrate that the high-performance media are able to upregulate mid and late hepatic markers, whereas embryoid body differentiation is only able to induce endodermassociated genes, supporting the idea that spontaneous EB lineage restriction is an unregulated and indirect differentiation process. For this reason, growth factor supplementation is essential if attempting to direct hepatic differentiation from cells isolated from EBs (Shirahashi et al., 2004; Baharvand et al., 2006; Lavon et al., 2004; Rambhatla et al., 2003; Schwartz et al., 2005) .
Figure 6
Representative immunofluorescent staining for ALB/CK18 in hESC-derived cells. Adherent cultures were grown for 2 weeks and stained with classic hepatic markers. ALB/CK18 coexpression is prominent in DOH, A d0-4 DOHW, and A d0-4 DOH cultures. Undifferentiated cells in complete and basal media were negative for ALB/CK18. The ALB/CK18-positive cells under the A 0-4 DOH conditions had distinct cuboidal morphology and appear to be binucleated (confirmed at higher magnification of 63X with DAPI counterstaining), indicative of hepatocyte-like cells. Abbreviations: ALB, albumin; CK18, cytokeratin-18. Scale Bar in all images = 150 µm.
In conclusion, our findings provide a simple system for further investigation into the differentiation pathways associated with hepatic lineage restriction. Here we describe an efficient process for directed differentiation of hESCs without the use of embryoid body development combined with the addition of select exogenous growth factors. Based on the emerging molecular biology of hESCs, the use of molecular growth factors in conjunction with gene-targeting approaches (for example, siRNA) may be other avenues to further differentiate hESCs. Future studies to expand threedimensional hESCs may also incorporate the use of threedimensional scaffolds that can combine selected growth factor supplementation within a controlled microenvironment for scaling up cell numbers for clinical research applications.
Materials and methods

Propagation of undifferentiated hESCs
Human embryonic stem cells (H1) were obtained from WiCell Research Institute (Madison, WI) and maintained following WiCell protocols. Briefly, cells were cultivated in gelatincoated, six-well plates in complete media consisting of DMEM-F12 supplemented with 20% KnockOut Serum Replacer, 200 mM L-glutamine, beta-mercaptoethanol, nonessential amino acids, 4 ng/ml basic fibroblast growth factor, and 0.12 ng/ml transforming growth factor-beta (TGF-β). Medium was changed daily. After collagenase IV treatment for 5-10 min at 37°C followed by mechanical dissociation, colonies were passaged weekly at a ratio of 1:6 on mitotically inactivated (X-irradiated, 6500 rad) mouse embryonic fibroblasts (MEFs).
Initiation of hESC differentiation
Directed differentiation was accomplished by culturing the hESCs on MEFs in the presence of various growth factors over a 2-week period. Human ES cells in complete media were allowed to attach overnight on the MEFs and subsequently cultured in basal media with various growth factor treatments (see Fig. 1 ). Basal media consists of complete media without the addition of b-FGF and TGF-β. Growth factor combinations consisted of permutations of up to five components added to the basal media: dexamathasone (10 −7 M); oncostatin M (10 ng/ml); hepatocyte growth factor (20 ng/ml); (Sigma, Atlanta, GA), activin A (50 ng/ml), and Wnt3A (100 ng/ml) (R&D Systems, Minneapolis, MN). Colonies were allowed to grow for 1 or 2 weeks in culture with media changed daily. As a comparison culture condition (control), embryoid bodies were formed by placing dissociated colonies in an ultralow attachment plate in the presence of basal media for 2 weeks with media changed every 2 days. Fig. 1 provides an illustration of the differentiation process.
Immunocytochemistry of hepatocyte-like cells
After 1 and 2 weeks in culture with various growth factor combinations, hESCs were stained for hepatospecific mar-kers to determine the extent of differentiation. Culture conditions were fixed with 4% paraformaldehyde in Dulbecco's phosphate-buffered saline (DPBS) with Ca 2+ and Mg 2+ for 15 min at room temperature. Cells were then rapidly washed three times with DPBS and permeabilized with SAP buffer (0.5% Saponin, 1% BSA, 0.1% sodium azide) (Sigma, St. Louis, MO) for 30 min at room temperature. After washing once with DPBS, cells were blocked with 3% (w/v) bovine albumin serum (BSA) for 30 min at room temperature to reduce nonspecific antibody binding. Subsequently, primary antibodies for hepatic identification were incubated overnight at 4°C with the addition of SSEA-4 as a counterstain for pluripotency. The primary antibodies, diluted in SAP buffer, are as follows: alpha-fetoprotein IgG1, 1:200 dilution (Abcam, Cambridge, MA); albumin IgG2b, 2.5 μg/ml (Abcam); cytokeratin 18 IgG1, 1:800 dilution (Abcam); and SSEA-4 IgG3, 1:200 dilution (Millipore, Chicago, IL). Cells were washed three times with DPBS and incubated with isotype-matched secondary antibodies, 1:1000 dilution in SAP buffer for 1 h at room temperature. The secondary antibodies are as follows: AlexaFluor 488 IgG1, AlexaFluor 488 IgG2b, and AlexaFluor 594 IgG3 (Invitrogen, Carlsbad, CA). Finally, the cells were washed four times in DPBS and visualized using the Leica TCS.SP2 confocal microscope system (Leica Microscope, Exton, PA).
RNA extraction and reverse transcriptase-polymerase chain reaction analysis
Total RNA was extracted from the cell pellets using the RNEasy kit (Qiagen, Valencia, CA) according to the manufacturer's instructions. The high-capacity cDNA reverse transcription kit and random primers (Applied Biosystems, Foster City, CA) were used to reverse transcribe total RNA to singlestranded cDNA for real-time PCR. Various genes were analyzed to determine hepatospecific markers including alpha-fetoprotein, albumin, forkhead box A2, transthyretin, hepatocyte nuclear factor-4, alpha-1-antitrypsin, cytokeratin 18, and beta-actin (SuperArray, Frederick, MD). Quantitative real-time PCR was performed using the SYBR Green PCR Master Mix (Qiagen) and the LightCycler System (Roche, Indianapolis, IN). cDNA samples, 1 μl in a 10 μl volume reaction, were analyzed for the gene of interest and for the housekeeping gene, beta-actin. Data represent samples in triplicate and displayed as mean ± SEM. Statistical analysis was completed by single-variable ANOVA followed by multiple comparison testing.
Human albumin secretion by differentiated hESCs
An ELISA Quantitation kit (Bethyl Laboratories, Montgomery, TX) was used to measure human albumin levels secreted in culture medium. Samples from three separate cultures were analyzed in duplicate for each condition. ELISA plates were read at 450 nm and the resulting data analyzed with a fourparameter curve-fitting computer program (KaleidaGraph). The absorbance of the basal medium was subtracted from each sample absorbance, and albumin concentration was determined from the standard curve. The final absorbance of the test samples was obtained after subtracting the zero absorbance and used to determine albumin concentrations secreted into the media. Data represent samples in triplicate and displayed as mean ± SEM. Statistical analysis was completed by ANOVA single factor analysis.
EROD assay
To determine the metabolic activity of the hESC-derived hepatic-like cells, an ethoxyresorufin O-de-ethylase assay was performed. Cytochrome P450 enzymes metabolize xenobiotic compounds with which they come in contact. After culturing the hESCs in high-performance media for 2 weeks, the EROD assay assessed the CYP1A2 activity. Briefly, cells were induced with 5 μM methylchloranthrene (Sigma) in respective media and cultured for 24 h. Cells were washed with PBS and cultured with 5 μM ethoxyresorufin (Sigma) for 2 h to initiate the EROD assay. The reaction was stopped with 20 mM NaOH and the supernatant was collected and measured on a fluorescence plate reader at 355 nm excitation and 581 nm emission. A standard curve of pure resorufin was used to calculate the activity of CYP1A2 in picomoles of resorufin formed per minute per million cells.
Cellular uptake and release of indocyanine green
Indocyanine green (ICG) is an inorganic anion that is used to evaluate liver function because it is nontoxic and eliminated exclusively by hepatocytes (Yamada et al., 2002) . Briefly, hESC-derived hepatic-like cells were cultured for 2 weeks in high-performance media and incubated with diluted ICG (Sigma) in media (1 mg/ml) for 30 min at 37°C. Cultures were washed and imaged with transmitted light to determine the amount of ICG uptake, indicated by green stain. Cells were cultured for an additional 6 h in culture media, washed, and imaged again to document release of cellular ICG stain.
Fluorescence-activated cell sorting analysis
To determine the percentage population positive for albumin and CK18, cells were processed and analyzed by fluorescentactivated cell sorting (FACS) (Becton Dickinson, Franklin Lakes, NJ). The highest performance media (A 4 DOH) were grown for up to 4 weeks and analyzed every other week for albumin and CK18 expression. Briefly, single-cell suspensions were used with fluorescent-conjugated antibodies against human albumin and cytokeratin 18. Cells were fixed with 1% paraformaldehyde (15 min, on ice), washed twice, permeabilized with SAP buffer (30 min, on ice), washed twice, blocked with 3% BSA (30 min, on ice), and washed again twice. Cell identification was confirmed by staining with primary antibodies against human albumin (R&D Systems), 0.5 μg/ml, and human cytokeratin 18 (Millipore), dilution 1:100, for 1 h on ice. Cells were washed twice and labeled with AlexaFluor goat anti mouse IgG (H+L) 488 (Invitrogen) for 1 h on ice, 1:1000 dilution. Finally, cells were washed three times with PBS and analyzed with CellQuest software (BD Biosciences). MEFs alone were run with each experiment as a negative control.
